Navigation Links
New lymphoma therapy may be more effective with fewer side effects
Date:11/3/2010

NEW YORK (Nov. 3, 2010) -- Diffuse large B-cell lymphoma (DLBCL) is a type of aggressive non-Hodgkin's lymphoma that accounts for approximately 40 percent of lymphomas among adults. If left untreated, it is fatal. The existing treatments have a cure rate that is slightly over 50 percent but destroy healthy cells along with the cancer cells.

Researchers at Weill Cornell Medical College have found a combination therapy that is more effective than traditional treatments and is able to kill the cancer cells without harm to surrounding tissues. In a paper published in the Journal of Clinical Investigation on Nov. 1, they report that by targeting a key lymphoma-causing factor called BCL6 with a specific inhibitor called RI-BPI in combination with either a histone deacetylases (HDAC) inhibitor or with a heat shock protein (Hsp90) inhibitor, they were able to suppress and in some cases eradicate human DLBCL in mice. The researchers said their findings provide the basis for rational, targeted combinational therapy for patients with DLBCL.

Dr. Ari Melnick, associate professor of medicine and director of the Raymond and Beverly Sackler Center for Biomedical and Physical Sciences at Weill Cornell Medical College, and his colleagues have been studying ways to kill lymphoma cancer cells more effectively and efficiently than standard treatments.

"Lymphomas are not easy to treat. The standard treatment using monoclonal antibodies and chemotherapy does not work for all patients and can cause undesirable side effects," says Dr. Melnick.

B cells are a type of white blood cell that produces antibodies to fight infections. BCL6 is a master regulatory factor that plays a critical role in keeping lymphoma cells alive. Dr. Melnick's study showed that therapeutic targeting of BCL6 with RI-BPI turned on another factor called EP300, a molecular switch that itself can turn on proteins that can restrain lymphoma cell growth and turn off other proteins that help lymphoma cells. The research team showed that turning on EP300 made lymphomas much more sensitive to the HDAC and Hsp90 inhibitors. Administering the drugs together is like "kicking both legs" of the lymphoma cells, so they cannot regain their balance. Thus, the combined effect of the drugs is much greater than either drug alone and has very powerful anti-tumor effects. In contrast, normal cells and tissues are not damaged by this form of combination therapy, since they are not dependent on these two "legs."

Finally, the scientists also discovered that EP300 is sometimes mutated in lymphomas, which shows that this gene may normally protect B cells from becoming cancerous. Detection of these mutations in patients is important since such tumors may not be responsive to RI-BPI. Dr. Melnick says that there is much more work to be done but he hopes that his research will lead to a better understanding of the mechanisms of cancer at the cellular level and better treatments for lymphomas and other cancers.


'/>"/>

Contact: Andrew Klein
ank2017@med.cornell.edu
212-821-0560
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
Source:Eurekalert

Related medicine news :

1. New class of drug kills lymphoma cells
2. Vitamin K may protect against developing non-Hodgkins lymphoma, say Mayo Clinic researchers
3. Scott & White Healthcare clinical trials target lymphoma, leukemia
4. Lifestyle factors significantly impact survival of non-Hodgkins lymphoma patients, study finds
5. Lifestyle Affects Survival in Non-Hodgkins Lymphoma
6. Study identifies promising treatment for aggressive lymphoma
7. Study shows Hodgkin lymphoma survivors lack post-treatment screening for other cancers
8. Lymphoma Survivors Often Miss Out on Follow-Up
9. Lymphoma patients with cardiovascular disease have increased risk of cardiac hospitalization
10. Study makes exciting progress in elucidating the mechanisms of bortezomib in lymphoma
11. Scott & White Healthcare study aimed at T-cell lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... The Wall Centre Dental team ... patients from Burnaby, BC. Patients in need of experienced orthodontics, laser dentistry, porcelain ... the esteemed team at Wall Centre Dental. Drs. Parviz Roshan, Siamak Tehrani, Milton ...
(Date:3/29/2017)... ... March 29, 2017 , ... Dr. Angela Cotey, a ... treatment and accepting new pediatric patients, with or without a referral. Dr. Cotey knows ... a better orthodontic outcome and experience. When patients receive early treatment, they may achieve ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... documenting and diagramming network and data center assets and audio-video devices has recently ... request new equipment shapes for free and download shapes and stencils from ...
(Date:3/29/2017)... ... ... HealthCareMandA.com will host an important webinar — Home Health & Hospice: Buying, Selling ... the webinar will also be made available following its live presentation. The webinar is ... popular targets for healthcare investors. This highly fragmented sector bounced back in 2016, as ...
(Date:3/29/2017)... ... March 29, 2017 , ... Hamlin Dental Group, multi-location ... now offering laser dental treatments. Dental lasers are safe and effective options, and can ... options and can improve the overall quality of care. , Dr. Hamid Reza of ...
Breaking Medicine News(10 mins):
(Date:3/30/2017)... DUBLIN , March 29, 2017 ... the opportunity to browse a comprehensive collection of company ... in-depth market research and analysis of their activities in ... ... The healthcare industry is going through a ...
(Date:3/30/2017)... March 30, 2017  Purcell Julie & Lefkowitz LLP, a ... investigating a potential breach of fiduciary duty claim involving the ... SGYP ). If you are a shareholder ... regarding this investigation, free of charge, please visit us at: ... ...
(Date:3/29/2017)... -- Research and Markets has announced the addition of ... offering. ... global gas chromatograph market to grow at a CAGR of 5.20% ... Chromatograph Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
Breaking Medicine Technology: